close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amarin Corporation plc - American Depositary Shares (NQ:AMRN)

14.03 -0.03 (-0.21%)
Streaming Delayed Price Updated: 10:20 AM EDT, May 19, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Amarin Corporation plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Amarin Reports 2026 First Quarter Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report First Quarter 2026 Financial Results and Host Conference Call on April 29, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Fourth Quarter and Full Year 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities
U.S. IPE Market Leadership Sustained; $70M Restructuring OPEX Savings on Pace for Mid-2026; Completed Transition to Fully Partnered Model Across All International Markets 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Third Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
-- Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanisms of Action -- 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Reports First Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
Action Taken to Maintain Company’s Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
– Data Further Advance Understanding of VASCEPA®/VAZKEPA® Potential Mechanism of Action and Utility as A Complementary Therapy for Residual Risk Reduction in Combination with Statins in Important... 
From Amarin Corporation plc
Via GlobeNewswire
News headline image
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
News headline image
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
1-For-20 Ratio Change Initiated to Increase Per Share Market Price of Amarin’s ADSs in Effort to Maintain Nasdaq Listing 
From Amarin Corporation plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today